NCT07122466Active, not recruiting
Early Treatment ctDNA Dynamics to Predict Response to Chemotherapy
Early Treatment ctDNA Dynamics to Predict Response to Chemotherapy in Patients With Advanced Pancreatic Cancer: a Prospective, Observational Pilot Study
Source: ClinicalTrials.gov · Last updated 26 Jun 2026
Brief summary (registry, in English)
This is a study that aims to understand whether a blood test measuring tumor DNA circulating in the bloodstream (circulating tumor DNA; ctDNA) shows a similar response as observed by a follow-up CT scan. To study this question, ctDNA will be measured at the same times as CT scans (just before the start of treatment, as well as 2 months after), and the response measured by the ctDNA change will be compared to the response seen on the changes between the CT scans. The goal is to make sure that ctDNA response correlates well with CT scan response measurement.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 24 (actual)
- First submitted
- 7 Aug 2025
- Start date
- 22 May 2023
- Primary completion date
- 17 Oct 2023
- Lead sponsor
- Northwell Health
- Diseases
- Pancreatic cancer
- NCT number
- NCT07122466
What you commit to
- Study type: Observational
- Participants enrolled: 24
- From 22 May 2023 to the primary completion date, 17 Oct 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- No exclusion criteria.
Who the study is looking for
- Prior/Concurrent Therapy Criteria
- Patients must be initiating a new treatment regimen for pancreatic cancer at the time of their initiation in the study
- Patients must have cytologic or histologic confirmation of pancreatic cancer
- Patients must have measurable radiographic evidence of metastatic disease
- Patients must be ≥18 years of age
- Patients must have an ECOG Performance Status 0-2.
- Patients must have adequate organ function for delivery of chemotherapy as evidenced by the following: Hgb ≥8 g/dL, platelets ≥ 75
- Patients must not have renal dysfunction that would prevent administration of IV contrast for radiographic assessment.
- Regulatory Criteria
- Patients must be informed of the investigational nature of this study and must sign and give written informed consent for this protocol in accordance with institutional and federal guidelines.
- Patients of all races, genders, \& ethnicities are eligible.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zuckerberg Cancer Center Coordinator of this site? Confirm its status | New Hyde Park | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.